Furthermore, we also found that a patient with a GBM harboring the IDH1 R132H mutation was exquisitely sensitive to a treatment regimen that included the pan-HDACi belinostat, especially when compared with other cases of GBM with wild-type IDH status. Here, IDH1 is linked to glioblastoma.